Akari Therapeutics plc ADS (NASDAQ: AKTX)
$1.2500
+0.1000 ( +8.70% ) 12.4K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$1.2500
Previous close
$1.1500
Volume
12.4K
Market cap
$33.09M
Day range
$1.1300 - $1.2600
52 week range
$0.9000 - $4.4000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 12 | May 16, 2024 |
| 10-q | Quarterly Reports | 58 | May 15, 2024 |
| 8-k | 8K-related | 11 | May 07, 2024 |
| 4 | Insider transactions | 1 | May 03, 2024 |
| 425 | Other | 3 | May 01, 2024 |
| 8-k | 8K-related | 13 | May 01, 2024 |
| 4 | Insider transactions | 1 | Apr 30, 2024 |
| 8-k | 8K-related | 11 | Apr 11, 2024 |
| 8-k | 8K-related | 12 | Apr 01, 2024 |
| 10-k | Annual reports | 74 | Mar 29, 2024 |